Production (Stage)
Cidara Therapeutics, Inc.
CDTX
$24.28
-$1.42-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.33% | -94.52% | -86.96% | -78.78% | -71.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.33% | -94.52% | -86.96% | -78.78% | -71.62% |
| Cost of Revenue | 143.44% | 80.04% | -46.10% | -58.11% | -59.25% |
| Gross Profit | -615.14% | -381.54% | -17.70% | -677.91% | -172.68% |
| SG&A Expenses | 71.54% | 51.80% | 7.25% | -16.65% | -28.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 132.82% | 83.73% | -24.95% | -41.29% | -45.90% |
| Operating Income | -279.30% | -237.10% | -29.16% | -104.82% | -27.13% |
| Income Before Tax | -604.85% | -579.40% | -273.27% | -665.43% | -20.00% |
| Income Tax Expenses | -- | -- | -97.50% | -108.01% | -94.49% |
| Earnings from Continuing Operations | -604.45% | -578.99% | -270.23% | -649.61% | -18.60% |
| Earnings from Discontinued Operations | 126.33% | -78.41% | 290.49% | -78.26% | -200.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -404.50% | -640.60% | -227.37% | -789.84% | -195.12% |
| EBIT | -279.30% | -237.10% | -29.16% | -104.82% | -27.13% |
| EBITDA | -280.31% | -237.93% | -29.14% | -105.60% | -27.39% |
| EPS Basic | -267.12% | -503.51% | -180.89% | -585.85% | -127.84% |
| Normalized Basic EPS | -96.90% | -100.98% | 7.35% | -83.37% | 2.69% |
| EPS Diluted | -266.89% | -502.81% | -180.85% | -584.48% | -80.97% |
| Normalized Diluted EPS | -96.90% | -100.98% | 7.35% | -46.77% | 15.23% |
| Average Basic Shares Outstanding | 93.55% | 45.07% | 21.79% | 16.69% | 24.72% |
| Average Diluted Shares Outstanding | 93.55% | 45.07% | 21.79% | 10.18% | 17.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |